7.02

10.34% -0.81

Pre-market: 7.19 0.17 +2.42%

Nextcure Inc (NXTC)

Overview News Price History Option Chain Financials Why NXTC Down? Discussions Forecast

Nextcure Inc stock is traded at $7.02, with a volume of 86,842. It is down -10.34% in the last 24 hours and down -33.27% over the past month. NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Previous Close:

$7.83

Open:

$7.83

24h Volume:

86,842

Relative Volume:

1.75

Market Cap:

$25.36M

Revenue:

Net Income/Loss:

$-55.84M

P/E Ratio:

-0.399

EPS:

-17.5951

Net Cash Flow:

$-49.61M

1W Performance:

-23.11%

1M Performance:

-33.27%

6M Performance:

-48.50%

1Y Performance:

+1,282%

1-Day Range:

$6.40

$7.90

1-Week Range:

$6.40

$10.71

52-Week Range:

$0.39

$15.74

Nextcure Inc Stock (NXTC) Company Profile

Name

Nextcure Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

240-399-4900

Address

9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD

Employee

Twitter

@nextcureinc

Next Earnings Date

2026-05-07

Latest SEC Filings

NXTC's Discussions on Twitter

Compare NXTC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NXTC Nextcure Inc	7.02	28.28M	0	-55.84M	-49.61M	-17.60
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-07-25	Upgrade	Ladenburg Thalmann	Neutral → Buy
Nov-04-22	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-22	Initiated	Ladenburg Thalmann	Buy
Mar-05-21	Upgrade	Truist	Hold → Buy
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform
Jul-16-20	Upgrade	The Benchmark Company	Hold → Buy
Jul-13-20	Downgrade	ROTH Capital	Buy → Neutral
Jul-13-20	Downgrade	SunTrust	Buy → Hold
Jun-01-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-01-20	Downgrade	The Benchmark Company	Buy → Hold
May-26-20	Initiated	JMP Securities	Mkt Outperform
Mar-24-20	Initiated	The Benchmark Company	Buy
Mar-02-20	Initiated	ROTH Capital	Buy
Jan-13-20	Initiated	SunTrust	Buy
Dec-05-19	Initiated	Needham	Buy
Nov-26-19	Initiated	BTIG Research	Buy
Jul-09-19	Initiated	BofA/Merrill	Buy
Jun-03-19	Initiated	Morgan Stanley	Overweight
Jun-03-19	Initiated	Piper Jaffray	Overweight

View All

Nextcure Inc Stock (NXTC) Latest News

May 25, 2026

NextCure (NXTC) Plunges Over 22% as Selling Pressure IntensifiesStraddle Setup - Newser

May 25, 2026

May 24, 2026